Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/120319
Author(s): Castro M.
Preto M.
Vasconcelos V.
Urbatzka R.
Title: Obesity: The metabolic disease, advances on drug discovery and natural product research
Publisher: Bentham Science Publishers
Issue Date: 2016
Abstract: Obesity is a global health threat. OECD reported that more than half (52%) of the adult population in the European Union is overweight or obese. Obesity and obesity-related co-morbidities have deep negative effects on morbidity, mortality, professional and personal quality of life. Healthcare costs represent a negative impact of this disease, with an associated economic cost of 100 billion US$ per year in the United States. The most prescribed drugs for obesity treatment worldwide are orlistat, and phentermine/topiramate extended release, while the major prescribed drug for the same disease in the US are exenatide and dapagliflozin. The so far developed drugs, targeting weight loss, have a long history of malignant secondary effects. There is still a lack of efficient and safe drugs to treat obesity and related metabolic complications since in many cases cure cannot be reached by bariatric surgery or healthy lifestyle habits. Terrestrial and aquatic organisms are a promising source of valuable, bioactive compounds, often with interest for human health. Some of the natural compounds or organisms have been used for centuries by humans as traditional medicine foods. In this review, we give insights into the adipose tissue function and development, and the progress in traditional anti-obesity pharmacotherapy. A major focus is to highlight the state of the art of natural compounds with anti-obesity properties and their potential as candidates for drug development; an overview is given about natural compounds derived from different marine animal sources, cyanobacteria, marine phytoplankton, fungus or plants. © 2016 Bentham Science Publishers.
Subject: anorexigenic agent
cycline
dapagliflozin
exendin 4
lorcaserin
low density lipoprotein
peroxisome proliferator activated receptor gamma
phentermine
pramlintide
sodium glucose cotransporter 2 inhibitor
somatomedin C
tetrahydrolipstatin
topiramate
uncoupling protein 1
zonisamide
biological product
Article
brown adipose tissue
carbohydrate metabolism
cell transdifferentiation
cognitive defect
food intake
health care cost
hyperplasia
hypertrophy
insulin sensitivity
lipid absorption
metabolic disorder
Monascus
mortality risk
obesity
plant leaf
plant seed
protein expression
quality of life
Undaria pinnatifida
Urochordata
weight gain
weight reduction
adipose tissue
animal
drug development
human
metabolism
obesity
Adipose Tissue
Animals
Biological Products
Drug Discovery
Humans
Obesity
URI: https://hdl.handle.net/10216/120319
Source: Current Topics in Medicinal Chemistry, vol. 16(23), p. 2577-2604
Related Information: info:eu-repo/grantAgreement/FCT/5876/147268/PT
Document Type: Artigo em Revista Científica Internacional
Rights: openAccess
Appears in Collections:CIIMAR - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
Castro M_2016.pdf493.7 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.